Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

CONCLUSIONS: Tofacitinib PMS safety data from submitted AE reports were consistent between PsA and RA, and aligned with its known safety profile. Exposure data (lower MR versus IR; estimation from commercial sales data), reporting bias, reporter identity, and regional differences in formulation use limit interpretation.PMID:37458964 | DOI:10.1007/s40744-023-00576-8

Source: Herpes - July 17, 2023 Category: Infectious Diseases Authors: Gerd R Burmester Laura C Coates Stanley B Cohen Yoshiya Tanaka Ivana Vranic Edward Nagy Irina Lazariciu All-Shine Chen Kenneth Kwok Lara Fallon Cassandra Kinch Source Type: research